If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
193
results.
Updated on
06/08/2025 [06:51:00]
Results 50 to 75 of 193
Absstract of: US2025241871A1
Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.
Absstract of: US2025242046A1
Disclosed herein are compositions comprising allogeneic, hypoimmunogenic chimeric antigen receptor (CAR)-targetable biomimetic nanovesicles (BioNVs) and methods of using the same for the treatment, prevention, and/or amelioration of cancer.
Absstract of: US2025242050A1
The present invention can provide a composition for treating gout or a method for treating gout, the composition containing a nano-drug in which a cyclodextrin moiety is conjugated to an amino group of a polymer, wherein a visible or near-infrared fluorophore is further conjugated to a carboxyl group of the polymer or the nano-drug further contains at least one gout therapeutic agent, which forms a complex together with the cyclodextrin moiety.
Absstract of: US2025242048A1
According to one embodiment, a particle-bound lipid nanoparticles includes a biodegradable lipid nanoparticle, a particle bound to an outer surface of the lipid nanoparticle, and an active substance bound to a surface of the particle.
Absstract of: US2025242049A1
It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem/progenitor cells or mesenchymal stem cells.
Absstract of: US2025242056A1
Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20×CD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of
Absstract of: WO2025159693A1
The present disclosure provides a lipid nanoparticle comprising a helper lipid at about 5 mol% to about 80 mol% relative to a total lipid content; an ionisable lipid at about 20 mol% to about 95 mol% relative to the total lipid content; a conjugated oligoelectrolyte at about 0.005 mol% to about 5 mol% relative to the total lipid content, wherein the conjugated oligoelectrolyte is configured to interact with at least the helper lipid in order 10 to stabilise the lipid nanoparticle. The present disclosure also provides methods of fabricating the lipid nanoparticle and methods of use thereof.
Absstract of: WO2025160412A1
Particles, aqueous dispersions, and compositions having high lipophilic component (LC) concentrations and high LC to surfactant ratios are described. The particles, aqueous dispersions, and compositions can be used to efficiently deliver active compounds and/or active ingredients through a variety of formulation types.
Absstract of: WO2025160552A1
A combinatorial cancer vaccine for cancer therapy includes a lipid nanoparticle that includes a plurality of pH sensitive protonatable or ionizable lipids, at least one of a TLR7 agonist, TLR 8 agonist or a TLR9 agonist complexed with and/or encapsulated by the pH sensitive protonatable or ionizable lipids, optionally a nucleic acid encoding a cancer antigen or neoantigen complexed or conjugated with and/or encapsulated by the pH sensitive protonatable or ionizable lipids, and optionally a stabilizing amount of at least one stabilizing polymer, polyethylene glycol or polysaccharide, or structural lipid that is conjugated to and/or complexed with the pH sensitive protonatable or ionizable lipids.
Absstract of: WO2025160462A1
Methods for treatment of hepatocellular carcinoma using formulations of tegavivint, alone or in combination with an immune checkpoint inhibitor.
Absstract of: WO2025160118A1
The present disclosure relates, in part, to hematopoietic stem cell (HSC) targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for delivery of nucleic acids and/or therapeutic agents to HSCs. In certain embodiments, the LNPs of the disclosure are suitable for in utero administration. In another aspect, the disclosure provides methods for treating, preventing, and/or ameliorating HSC-related disease and/or disorders, including but not limited to hemoglobinopathies and immunodeficiencies.
Absstract of: WO2025160177A1
The present disclosure provides compositions which facilitate preferential targeting or delivery of a therapeutic agent to a particular organ, cell, or tissue. The presently disclosed compositions comprise lipid nanoparticles formed from a covalent-bond forming lipid, a cationic lipid, and, in some embodiments, a steroid or sterol, a phospholipid, and a PEG lipid.
Absstract of: US2025242032A1
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic compound and insulin. The aggregate can be further prepared into an insulin oral preparation. The oral preparation can be used for reducing the blood glucose level of a mammal as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the insulin oral preparation prepared by means of the method can effectively protect insulin against the three physiological barriers of an oral uptake pathway, is stable in the gastrointestinal tract environment, is subjected to a dynamic chemical exchange reaction with intestinal mucin in intestinal juice and the sulfhydryl groups of proteins inside and outside an epithelial cell membrane by means of the molecular bond of polychalcogen on the surface, and enters the circulation system from the intestinal epithelial cell to achieve the effect of reducing blood glucose. When being orally administered, the insulin oral preparation has high bioavailability, has a good hypoglycemic effect in mammals, and can be used for treating diabetes.
Absstract of: US2025242030A1
Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.
Absstract of: US2025242045A1
Disclosed herein are cell-targeting complexes that are coated on the surface with target specific antibodies for induction of biological stimulus in target cells/tissue/organs. In some embodiments, the cell-targeting complex involves non-nucleated (e.g. platelets, red blood cells (RBC)) or enucleated cells that have been thiolated, streptavidinylated, and then coated with biotinylated antibodies. In some embodiments, the cell-targeting complex involves multilayer alginate hydrogel beads that have been coated with polyanionic proteins using a polycation, which is then thiolated, streptavidinylated, and then coated with biotinylated antibodies.
Absstract of: US2025242015A1
The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-E1-A-E2-U-H and H-U-E1-A-E2-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.
Absstract of: US2025242028A1
A metal boride nanoparticle is provided, which has dual functions of tumor diagnosis and therapeutic treatment. A surface of the metal boride nanoparticle is modified with antibodies, bioprobes, or coated with a biological cell membrane, and the antibodies or the bioprobes have a specificity for binding to receptors on specific tumor cells.
Absstract of: WO2025160594A1
A method for immunizing a subject against a pathogen, comprising the steps of: (1) administering to the subject an effective amount of a prime vaccine, wherein the prime vaccine comprises one or more mRNA constructs encoding one or more immunogens from the pathogen; and (2) administering to the subject an effective amount of a boost vaccine, wherein the booster vaccine comprises a non-mRNA vaccine modality, such as a recombinant protein, against the pathogen, wherein the boost vaccine comprises the immunogen or immunogens encoded in one or more mRNA constructs in the prime vaccine, or wherein the boost vaccine comprises the immunogen or immunogens that are not the same as encoded in one or more mRNA constructs in the prime vaccine, wherein the boost vaccine is administered after the administration of the prime vaccine.
Absstract of: WO2025159411A1
An embodiment of the present invention relates to: a vaccine nanoparticle comprising an assembly of cell-penetrating peptides (CPPs) conjugated with deoxycholic acid (DOCA); a method for preparing same; and a vaccine composition for preventing or treating cancer, comprising same. The effects of migration, maturation, and antigen presentation through MHC I in dendritic cells, as well as antigen-specific T cell immune responses through the nanoparticle of the present invention were evaluated in vitro and in vivo. An improved effect was also confirmed through repolarization of tumor-associated macrophages. Additionally, the effect of combination therapy with an immune checkpoint inhibitor was confirmed in a tumor-bearing animal model. The nanoparticle of the present invention induces antigen-specific immunity and macrophage repolarization, thereby improving anti-tumor immunotherapy, and thus can be applied as an mRNA cancer vaccine.
Absstract of: WO2025159588A1
The present invention relates to a gene delivery platform for multi-organ sequential targeting oral administration, and to a gene delivery platform having a layer-by-layer chylomicron-mimicking self-assembly (lbl-CMSA), which is a lipid nanoparticle having a double-layer structure. A gene delivery platform for oral administration according to the present invention allows a second layer containing the outermost bile acid to exhibit high durability in the gastrointestinal tract even under various pH and enzyme actions, allows a gene drug encapsulated by an intestinal active target mechanism of bile acid to be primarily delivered to intestinal cells, and allows a first layer containing apolipoprotein to be delivered to lymphatic vessels through a chylomicron-mimicking pathway, thereby allowing the gene drug encapsulated therein to secondarily reach a target organ via a circulatory pathway in the body. Therefore, the gene delivery platform for oral administration of the present invention can be used as an effective oral administration formulation having increased bioavailability by loading, on the platform, a combination of gene therapeutic agents sequentially targeting the intestine and various organs.
Absstract of: US2025241943A1
The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
Absstract of: US2025241863A1
In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.
Absstract of: US2025241848A1
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.
Absstract of: US2025242059A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Nº publicación: US2025241886A1 31/07/2025
Applicant:
NANO TARGETING & THERAPY BIOPHARMA INC [TW]
SCINOPHARM TAIWAN LTD [TW]
NANO TARGETING & THERAPY BIOPHARMA INC,
SCINOPHARM TAIWAN LTD
Absstract of: US2025241886A1
The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.
BOPI
Electronic site
